Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax's vaccine hasn't been approved yet, but that hasn't stopped the European Commission from signing a contract for at least 100 million doses.

Novavax Stock Jumps After Europe Approves Contract for Covid Vaccine

GAITHERSBURG, Md., Aug. 4, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.

Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine

Inari Medical

Pfizer

Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.

3 COVID Stocks That Could Soar Higher

On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?

Novavax stock has declined by almost 12% over the last week (five trading days), compared to the S&P 500 which has remained roughly flat over the same period. The stock is also down by almost 16% over the last month (21 trading days).

Novavax Stock: Buy The Dip?

Investors might hope that the spread of the Delta variant will boost NVAX stock, but a recent news release is likely to hinder progress. The post Covid-19 Vaccine Dose Delay Spells Even More Trouble for Novavax Stock appeared first on InvestorPlace.

Covid-19 Vaccine Dose Delay Spells Even More Trouble for Novavax Stock

Arcturus Therapeutics

Inovio Pharmaceuticals

Moderna

Ocugen, Inc.

Vaxart

These players delivered triple- and quadruple-digit gains.

Can Last Year's Biggest Vaccine Stocks Crush the Market Again?

The latecomer could still carve out a spot for itself among the big vaccine makers.

How Novavax Could Shake Up the COVID Vaccine Market

Until Novavax secures FDA approval of its Covid-19 vaccine, investors should not buy NVAX stock, which has fallen 10% in recent days. The post Don't Buy Novavax Until Its Covid-19 Vaccine Wins FDA Approval appeared first on InvestorPlace.

Don't Buy Novavax Until Its Covid-19 Vaccine Wins FDA Approval

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Novavax (NVAX) to Report a Decline in Earnings: What to Look Out for

Abbott Labs

You have the power to turn a negative event into something positive.

Anxious About a Market Crash? Start Doing These 3 Things Right Now

They will give us clues about when to expect billions in revenue.

3 Things That Will Make or Break Novavax's Earnings Report Next Week

While NVAX stock may enjoy increased relevance on paper due to the delta variant, investors should think about the bigger picture. The post Novavax Stock May Not Get the Delta Varient Bump Investors Need appeared first on InvestorPlace.

Novavax Stock May Not Get the Delta Varient Bump Investors Need

Pubmatic

As the Dogecoin bubble bursts, these high-growth stocks are blossoming.

It's Game Over for Dogecoin, but These Stocks Can Still Go to the Moon

BioNTech SE

Owens & Minor

Despite sizzling year-to-date gains, these stocks are surprisingly inexpensive.

3 Red-Hot Stocks That Are Still Dirt Cheap

Catalyst Pharmaceuticals

Yes, but it often doesn't have much to do with revenue.

Do Earnings Reports Matter for Biotech Stocks?

Concerns about the delta variant are rising.

Why BioNTech, Moderna, and Novavax Stocks Soared This Week

Novavax is worth roughly 100% more. NVAX stock is worth $419 given its high efficacy, cheap price, easy storage and cheap valuation compared to Moderna.

Novavax Is Worth 100% More Given Its Prospects and Value Metrics

Novavax stock has rallied by almost 12% over the last week (five trading days), compared to the S&P 500 which was down by almost 3% over the same period. The stock is also up by a solid 85% year-to-date.

Why Novavax Stock Should Continue To Rally

QuidelOrtho Corp

Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the Move Today appeared first on InvestorPlace.

Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the Move Today

The stock price of Novavax, Inc. (NASDAQ: NVAX) increased by 12.78% yesterday. This is why it happened.

NVAX Stock Increased 12.78%: Why It Happened

Aethlon Medical

Allied Healthcare Products

Mer Telemanagement Solutions

Oragenics

Stocks begin week with the market selling off; why? The post This Is Why Stocks Are Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

This Is Why Stocks Are Down Today

Novavax, Inc. (NASDAQ: NVAX) shares rallied higher Monday after renewed COVID-19 concerns. The new Delta variant has been spreading and is a major concern with it recently becoming the dominant strain of COVID-19.

Is Novavax Breaking Out After The Rally?

Co-Diagnostics

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Why Coronavirus Stocks Are Zooming Higher Today

NVAX stock has had a turbulent 2021, but with its Covid-19 vaccine expected to go into product in Q4, growth looms. The post Plenty of Upside Potential Looms Ahead of Novavax Stock's Bumpy Road appeared first on InvestorPlace.

News for Novavax Stock (NVAX)